Clinical Nuclear Medicine

Skip Navigation LinksHome > June 2012 - Volume 37 - Issue 6 > Ipilimumab-Induced Colitis on FDG PET/CT
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318248549a
Interesting Images

Ipilimumab-Induced Colitis on FDG PET/CT

Lyall, Ashima MD; Vargas, Herbert Alberto MD; Carvajal, Richard D. MD; Ulaner, Gary MD, PhD

Collapse Box


Abstract: A 52-year-old woman with metastatic melanoma was treated with ipilimumab. After 2 cycles of treatment, she developed watery diarrhea, sweats, and chills. An FDG PET/CT study demonstrated new FDG-avid (maximum standardized uptake value 15.6) diffuse colonic wall thickening, suggestive of ipilimumab-induced colitis. The patient was treated with systemic steroids, with subsequent resolution of her symptoms. Based on the response to steroids, the diagnosis of ipilimumab-induced enterocolitis was made. Ipilimumab may cause several immune-mediated toxicities, the most common of which is enterocolitis. Physicians interpreting FDG PET/CT examinations of patients treated with ipilimumab should be aware of these FDG-avid immune-mediated toxicities.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.